Vascular effects of erythropoietin and anemia correction

Seminars in Nephrology

Volumn 20, Issue 4, 2000, Pages 356-363

  Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD VESSEL FUNCTION; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VASOCONSTRICTION;

EID: 0033943245     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Erslev AJ, Besarab A: Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:622-630, 1997
2. Fisher JW: Erythropoietin: Physiologic and pharmacologie aspects. Proc Soc Exp Biol Med 2 16:358-369, 1997
3. Baldwin MD, Zhou XJ, Ing TS, et al: Erythropoietin ameliorates anemia of cisplatin-induced acute renal failure. AS AID 44:44-47, 1998
4. Vaziri ND, Kaupke CJ, Barton CH, et al: Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 92:35-40, 1992
5. Zhou XJ, Vaziri ND: Erythropoietin metabolism and pharmacokinetics in experimental nephrosis. Am J Physiol 263: F812-F815, 1992
6. Gansevoort RT, Vaziri ND, de Jong PE: Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am J Kidney Dis 28:274-277, 1996
7. Drueke TB: Modulating factors in hematopoietic response to erythropoietin. Am J Kidney Dis 18:87-92, 1991
8. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of combined phase I and II clinical trials. N Engl J Med 316:73-78, 1987
9. Eschbach JW, Abdulhadi MH, Browne JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Int Med 111:992-1000, 1989
10. Winearls CG: Historical review of the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 10:3-9, 1995 (suppl 2)
11. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2:927-936, 1991
12. Buckner FS, Eschbach JW, Haley NR, et al: Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 3:947-955, 1990
13. Raine AE, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18:76-83, 1991
14. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
15. Raine AE: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1:97-100, 1988
16. Steffen HM, Brunner R, Muller R, et al: Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 76:292-298, 1989
17. Martin J, Moncada S: Blood pressure, erythropoietin, and nitric oxide. Lancet 1:644, 1988
18. Neff MS, Kim KE, Persoff M, et al: Hemodynamics of uremic anemia. Circulation 43:876-883, 1971
19. Samtleben W, Baldamus CA, Bommer J, et al: Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol 66:114-122, 1988
20. Vaziri ND, Zhou XJ, Naqvi F, et al: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113-E122, 1996
21. Vaziri ND, Zhou M, Smith J, et al: In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269: F838-F845, 1995
22. Kaupke CJ, Kirn S, Vaziri ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4:1874-1878, 1994
23. Blood pressure and erythropoietin. Lancet 1:351-352, 1988
24. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6:103-107, 1993
25. Takahashi K, Totsune K, Imai Y, et al: Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sei (Colch) 84:47-50, 1993
26. Carlini RG, Dusso AS, Obialo CI, et al: Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43:1010-1014, 1993
27. Bode-Boger SM, Boger RH, Kuhn M, et al: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50:12551261, 1996
28. Katoh K, Mizuno K, Hashimoto S, et al: Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sei 54:L253-L259, 1994
29. Zhou XJ, Pandian D, Wang XQ, et al: Erythropoietininduced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol 8:901-905, 1997
30. Hon G, Vaziri ND, Kaupke CJ, et al: Lack of a fastacting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Organs 19:188-191, 1995
31. Hand MF, Haynes WG, Johnstone HA, et al: Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806-813, 1995
32. Lai KN, Lui SF, Leung JC, et al: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57:394400, 1991
33. Wagner OF, Christ G, Wojta J, et al: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068, 1992
34. Lebel M, Lacasse MS, Lariviere R, et al: Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 20: 939-951, 1998
35. Brochu E, Lacasse MS, Lariviere R, et al: Differentia] effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10:1440-1446, 1999
36. Eggena P, Willsey P, Jamgotchian N, et al: Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261:E642-E646,1991
37. Bode-Boger SM, Boger RH, Kuhn M, et al: Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 20:S25-S28, 1992 (suppl)
38. Lebel M, Kingma I, Grose JH, et al: Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 9:97-104, 1998
39. Resnick LM: Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders. Am J Med 93:S11-S20, 1992 (suppl 2A)
40. Vasdev S, Thompson P, Triggle C, et al: Fura-2 used as a probe to show elevated intracellular free calcium in platelets of Dahl-sensitive rats fed a high salt diet. Biochem Biophys Res Commun 154:380-386, 1988
41. Krzcsinski JM, Du F, Pequeux ML, et al: Plasma Na-K ATPase inhibitor activity and intracellular ions during hemodialysis. Int J Artif Organs 16:23-30, 1993
42. Matuura T, Kohno M, Kanayama Y, et al: Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. Biochem Biophys Res Commun 143:1012-1017, 1987
43. Kaupke CJ, Zhou XJ, Vaziri ND: Cytosolic ionized magnesium concentration in end-stage renal disease: Effect of hemodialysis. ASAIO J 39:M614-M617, 1993
44. Altura BM, Altura BT: Role of magnesium in the pathogenesis of hypertension: Relationship to its actions on cardiac and vascular smooth muscle, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY, Raven, 1990, pp 1003-1025
45. Vaziri ND, Ni Z, Wang XQ, et al: Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol 274:F642-F649, 1998
46. Van Geet C, Van Damme-Lombaerts R, Vanrusselt M, et al: Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilization in uraemic children: A possible link? Thromb Haemost 64:7-10, 1990
47. Neusser M, Tepel M, Zidek W: Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 27:1233-1236, 1993
48. Tang WW, Stead RA, Goodkin DA: Effect of Epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18:263-273, 1998
49. Marrero MB, Venema RC, Ma H, et al: Erythropoietin receptor-operated Ca2+ channels: Activation by phospholipase C-gamma. Kidney Int 53:1259-1268, 1998
50. Miller BA, Cheung JY: Mechanisms of erythropoietin signal transduction: Involvement of calcium channels. Proc Soc Exp Biol Med 206:263-267, 1994
51. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39:259-265, 1991
52. Ni Z, Wang XQ, Vaziri ND: Nitric oxide metabolism in erythropoietin-induced hypertension: Effect of calcium channel blockade. Hypertension 32:724-729, 1998
53. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by cultured human endothelial cells. Hypertension 33:894-899, 1999
54. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745, 1995
55. Gogusev J, Zhu DL, Herembert T, et al: Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199:977-983, 1994
56. Ammarguellat F, Gogusev J, Drucke TB: Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 11:687-692, 1996
57. Kaupke CJ, Butler GC, Vaziri ND: Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 3:1672-1679, 1993
58. Vaziri ND, Zhou XJ, Laio SY: Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266:F360-F366, 1994
59. Mann JFE: What are the short-term and long-term consequences of anemia in CRF patients. Nephrol Dial Transplant 14:29-36, 1999 (suppl 2)